A-S Medication Solutions

Compañía farmacéutica56 productos registrados

productos registrados

3.447.028

notificaciones totales

425

retiradas registradas

65,4%

graves en total

Productos

mostrando 56 de 56

Producto	Aprobado	Notificaciones ↓	Señal principal	Retiradas
prednisone —	1972	491.157	Lupus eritematoso sistémico	11
levothyroxine sodium —	2000	308.680	Palpitaciones	100
ibuprofen capsules 200 mg —	—	195.145	Enfermedad renal crónica	1
montelukast —	2012	171.338	Asma	14
naproxen —	1987	162.981	Sinovitis	12
spironolactone —	1979	137.410	hiperpotasemia	11
levetiracetam —	2003	130.496	Resistencia a múltiples fármacos	18
celecoxib —	1998	129.432	Artropatía psoriásica	4
diazepam —	1963	119.417	Abuso de drogas	13
montelukast sodium —	2012	118.894	trastorno obstructivo de las vías respiratorias	14
formoterol fumarate dihydrate —	2006	114.158	trastorno obstructivo de las vías respiratorias	2
amoxicillin —	1974	99.955	Enfermedad renal terminal	20
tadalafil —	2019	98.103	Hipertensión arterial pulmonar	0
budesonide and formoterol fumarate dihydrate —	—	95.176	trastorno obstructivo de las vías respiratorias	1
dulaglutide —	2014	86.770	Dosis insuficiente accidental	3
emtricitabine —	2015	77.542	Desmineralización ósea	3
carbamazepine —	1986	66.038	Epilepsia	12
insulin aspart —	2000	64.485	Disminución de la glucosa en sangre	5
metronidazole —	1982	63.743	Infección por Clostridium difficile	15
letrozole —	1997	60.586	cáncer de mama metastásico	2
fluticasone propionate and salmeterol xinafoate —	—	59.089	trastorno obstructivo de las vías respiratorias	0
dapagliflozin —	2014	56.693	cetoacidosis diabética	1
tenofovir alafenamide —	2015	41.643	Desmineralización ósea	0
naltrexone —	1984	39.971	Alcoholismo	17
insulin detemir —	2005	38.856	Aumento de la glucosa en sangre	1
emtricitabine and tenofovir alafenamide —	—	35.132	Desmineralización ósea	0
fenofibrate —	2001	34.581	Enfermedad renal crónica	11
canagliflozin —	2013	30.943	Infección del pie diabético	1
amoxicillin and clavulanate potassium —	—	26.702	Colestasis	5
atomoxetine —	2002	26.564	Blefaroespasmo	19
azelastine —	2000	21.326	Problema del mecanismo de administración del producto	9
cephalexin —	1971	21.106	Anemia nefrogénica	24
cobicistat —	2012	20.686	lesión dental	0
moxifloxacin —	2001	19.663	Sibilancias	38
moxifloxacin hydrochloride —	2001	19.655	Sibilancias	0
desoximetasone —	1980	18.541	Anticuerpo anti-péptido citrulinado cíclico positivo	13
bictegravir sodium, emtricitabine, and tenofovir alafenamide fumarate —	—	17.624	Disminución de la densidad ósea	0
amitriptyline hydrochloride —	1977	16.938	dolor en el lugar de infusión	0
trazodone hydrochloride —	1981	15.321	Intento de suicidio	0
thyroid, porcine —	—	10.359	Palpitaciones	0
azelastine hydrochloride —	2000	10.154	Problema del mecanismo de administración del producto	4
naltrexone hydrochloride —	1984	9868	insatisfacción del paciente con el tratamiento	1
beclomethasone dipropionate —	1976	9839	Molestia nasal	7
colesevelam hydrochloride —	2000	9134	Ningún evento adverso	0
triazolam —	1982	8566	Sopor	0
etodolac —	1996	5914	Enfermedad renal crónica	2
betamethasone valerate —	1967	4388	Flatulencia vaginal	0
clindamycin hydrochloride —	1970	3461	Erupción maculopapular	3
sodium zirconium cyclosilicate —	2018	3424	Potasio en sangre anormal	0
clindamycin phosphate topical —	—	3384	Hidradenitis	5
cefuroxime axetil —	1987	3377	Linfedema	0
levalbuterol hydrochloride —	1999	3293	Asma	0
norethindrone acetate and ethinyl estradiol and ferrous fumarate —	—	2865	metrorragia	0
beclomethasone dipropionate hfa —	—	2734	Problema con el sistema de administración del dispositivo	3
insulin lispro-aabc —	2020	1984	Irritación en el lugar de infusión	0
darunavir ethanolate and cobicistat —	—	1744	Desmineralización ósea	0

Historial de retiradas · 50 registradas

Fecha	Clase	Motivo	Empresa
28 may 2026	II	CGMP Deviations	Ajanta Pharma USA Inc
30 abr 2026	II	Labeling: Label Mix-Up: Atomoxetine HCl 25mg Capsule incorrectly labeled as Atomoxetine HCl 10mg Capsule.	Safecor Health, LLC
20 abr 2026	II	Chemical contamination; presence of lead and lithium above specification	Acella Pharmaceuticals, LLC
26 feb 2026	II	Subpotent Drug	MACLEODS PHARMA USA, INC
31 dic 2025	II	Product Mix-Up: A single bottle of this lot was reported by a pharmacy to contain 88 mcg tablets instead of 150 mcg tablets.	Alvogen, Inc
18 dic 2025	II	Presence of particulate matter - Glass like particles.	Imprimis NJOF, LLC
13 oct 2025	II	Subpotent drug; Clavulanate Potassium component	Teva Pharmaceuticals USA, Inc
15 sept 2025	II	Failed Dissolution Specifications.	Amerisource Health Services LLC
5 ago 2025	II	Presence of foreign substance: identified as aluminum.	SUN PHARMACEUTICAL INDUSTRIES INC
29 jul 2025	II	Subpotent drug	Pfizer
20 jun 2025	II	Subpotent Drug: Assay below the approved specification	ACCORD HEALTHCARE, INC.
20 jun 2025	II	Subpotent Drug: Assay below the approved specification	ACCORD HEALTHCARE, INC.
20 jun 2025	II	Subpotent Drug: Assay below the approved specification	ACCORD HEALTHCARE, INC.
20 jun 2025	II	Subpotent Drug: Assay below the approved specification	ACCORD HEALTHCARE, INC.
20 jun 2025	II	Subpotent Drug: Assay below the approved specification	ACCORD HEALTHCARE, INC.
28 may 2025	II	Lack of Assurance of Sterility	Apotex Corp.
23 may 2025	II	Failed Impurities/Degradation Specifications An out-of-specification result was observed in the related substance test at the sixth month of stability analysis. The individual impurity was identified to be Cephalexin Glucose Adduct.	Ascend Laboratories, LLC
23 may 2025	II	Failed Impurities/Degradation Specifications An out-of-specification result was observed in the related substance test at the sixth month of stability analysis. The individual impurity was identified to be Cephalexin Glucose Adduct.	Ascend Laboratories, LLC
13 may 2025	II	Presence of Foreign Tablets/Capsules: manufacturer recalled because one tadalafil 5mg tablet was found in 500 count bottle of Celecoxib 200 mg capsules	AvKARE
9 may 2025	II	Presence of Foreign Tablets/Capsules; customer complaint found one Tadalafil 5mg tablet inside a sealed 500-count bottle of Celecoxib 200mg capsule	Alembic Pharmaceuticals Limited
10 abr 2025	II	Subpotent	ACCORD HEALTHCARE, INC.
10 abr 2025	II	Subpotent	ACCORD HEALTHCARE, INC.
13 mar 2025	I	LABELING: LABEL MIX-UP: The infusion bag is incorrectly labeled as Levetiracetam in 0.82% Sodium Chloride Injection 500 mg/100 mL, while the aluminum overwrap packaging correctly identifies the product as Levetiracetam in 0.75% Sodium Chloride Injection 1,000 mg/100 mL.	Dr. Reddy's Laboratories, Inc.
13 mar 2025	II	CGMP Deviations	Glenmark Pharmaceuticals Inc., USA
13 mar 2025	II	CGMP Deviations	Glenmark Pharmaceuticals Inc., USA
7 mar 2025	II	Super-Potent Drug: Out of specification potency results were obtained.	Mylan Institutional, Inc.
25 feb 2025	II	Presence of Foreign Tablets/Capsules.	A-S Medication Solutions LLC
29 ene 2025	II	CGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.	Glenmark Pharmaceuticals Inc., USA
29 ene 2025	II	CGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.	Glenmark Pharmaceuticals Inc., USA
29 ene 2025	II	CGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.	Glenmark Pharmaceuticals Inc., USA
29 ene 2025	II	CGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.	Glenmark Pharmaceuticals Inc., USA
29 ene 2025	II	CGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.	Glenmark Pharmaceuticals Inc., USA
29 ene 2025	II	CGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.	Glenmark Pharmaceuticals Inc., USA
29 ene 2025	II	CGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.	Glenmark Pharmaceuticals Inc., USA
29 ene 2025	II	CGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.	Glenmark Pharmaceuticals Inc., USA
29 ene 2025	II	CGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.	Glenmark Pharmaceuticals Inc., USA
29 ene 2025	II	CGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.	Glenmark Pharmaceuticals Inc., USA
29 ene 2025	II	CGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.	Glenmark Pharmaceuticals Inc., USA
29 ene 2025	II	CGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.	Glenmark Pharmaceuticals Inc., USA
29 ene 2025	II	CGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.	Glenmark Pharmaceuticals Inc., USA
29 ene 2025	II	CGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.	Glenmark Pharmaceuticals Inc., USA
20 dic 2024	II	Failed Impurities/Degradation Specifications: Out of specifications result observed in the drug substance for impurity test during 3-month long term stability study.	Lupin Pharmaceuticals Inc.
19 nov 2024	II	Subpotent and Superpotent Drug	Mylan Institutional, Inc.
19 nov 2024	II	Subpotent and Superpotent Drug	Mylan Institutional, Inc.
19 nov 2024	II	Subpotent and Superpotent Drug	Mylan Institutional, Inc.
19 nov 2024	II	Subpotent and Superpotent Drug	Mylan Institutional, Inc.
19 nov 2024	II	Subpotent and Superpotent Drug	Mylan Institutional, Inc.
19 nov 2024	II	Subpotent and Superpotent Drug	Mylan Institutional, Inc.
18 nov 2024	II	Superpotent Drug and Subpotent Drug: potency failures obtained	Viatris Inc
18 nov 2024	II	Superpotent Drug and Subpotent Drug: potency failures obtained	Viatris Inc

Clase I = probabilidad razonable de daño grave · Clase II = temporal o reversible · Clase III = improbable que cause daño.

Estado de registro

Algunos productos de A-S Medication Solutions no están registrados por la FDA para uso humano. Para las sustancias no registradas (péptidos, SARM sin registro humano) no existe ningún proveedor legítimo para uso humano. La ausencia de una vía de aprovisionamiento es la información de seguridad.